EGFR and lung adenocarcinoma: The ISEL-associated IPASS trial, which identified an EGFR-activating mutation [5], showed that the EGFR-TKI was more effective in patients with lung adenocarcinoma, who had EGFR-TKI-sensitizing mutations (mEGFRs) [6].